1. Kahneman D . Thinking, fast and slow. London: Penguin, 2011.
2. The discipline of cost‐benefit analysis;Sen;J Legal Stud,2000
3. Pant S , Visintini S . Drugs for rare diseases: a review of national and international health technology assessment agencies and public payers’ decision-making processes. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2018.
4. Caring for identified versus statistical lives: an evolutionary view of medical distributive justice;Moore;Ethol Sociobiol,1996
5. Firth I , Schirrmacher H , Zhang K . Exploring the financial sustainability of gene therapies. office of health economics consulting reports. London: Office of Health Economics, 2021.